Table 1.
Review of available case series.
| Sex | Age | Onset Phenotype | N° Relapses | Current EDSS | Other Antibody | Spine Lesion | Brain Lesion | Treatment | |
|---|---|---|---|---|---|---|---|---|---|
| Hyun et al., 2017 [6] | M | 32 | LETM | 4 | 7 | Anti-SS-A Ab (+), antinuclear Ab (+), speckled pattern | NA | None | AZA |
| Höftberger et al., 2014 [7] | F | 58 | LETM + ON | 1 | 2 | No | C1-C5 | None | RTX |
| F | 50 | LETM + ON | 1 | 2 | No | C4-T2 | Aspecific WML | AZA | |
| Yan et al., 2016 [8] | F | 15 | LETM + ON | 3 | 7 | No | C4-conus | Large MS-like lesions | CS, AZA |
| F | 36 | LETM | 8 | 8 | No | T1-conus | Small MS-like lesions | RTX | |
| F | 18 | LETM + ON | 8 | 8.5 | Anti-SS-A A/B, Anti-Tg, anti-TPO | C1-conus | Small MS-like lesions | Met HCQ | |
| F | 60 | LETM | 6 | 8.5 | No | C2-conus | Small MS-like lesions | CS, AZA | |
| F | 49 | LETM | 3 | 7.5 | No | C1-conus | Small MS-like lesions | CS, AZA | |
| F | 33 | ON | 6 | 3 | No | C3-conus | Large MS-like lesions | CS, AZA | |
| F | 15 | ON | 7 | 1 | No | C1-conus | ADEM-like | CS, AZA | |
| F | 20 | LETM + ON | 10 | 6.5 | No | C1-conus | ADEM-like | CS, AZA | |
| F | 30 | LETM | 4 | 7.5 | No | C1-conus | ADEM-like | RTX | |
| F | 36 | LETM | 6 | 8 | No | C1-T12 | Small MS-like lesions | RTX | |
| Ishikawa et al., 2019 [10] | F | 24 | ON | 3 | NA | NA | NA | NA | CS, Iv Ig, AZA |
Ab, antibody; ADEM, acute disseminated encephalomyelitis; AZA, azathioprine; CS, corticosteroids; EDSS, Expanded Disability Status Scale; F, female; HCQ, hydroxychloroquine; Iv Ig, Intravenous immunoglobulins; JC, juxtacortical white matter; LETM, longitudinally extensive transverse myelitis; M (gender), male; Met, Methotrexate; MS, multiple sclerosis; NA, not available; NMOSD, neuromyelitis optica spectrum disorder; ON: optic neuritis; RTX, rituximab; tg, thyroglobulin; TPO, thyroperoxidase; WML, white matter lesion.